Adial Pharmaceuticals initiated at Maxim

Adial Pharmaceuticals initiated with a Buy at Maxim. Maxim analyst Jason McCarthy initiated Adial Pharmaceuticals with a Buy rating and a price target of $5, citing the company’s development of AD04 – an ultra-low-dose ondansetron therapy for the treatment of alcohol use disorder. The analyst notes that the phase 2b study has already demonstrated a “reduced drinks per day” and “decreased percent heavy drinking days” responses, with phase 3 study expected in the future. McCarthy further cites the large potential under-served market of 35M people in the U.S. suffering from alcohol use disorder.
https://thefly.com/landingPageNews.php?id=2813303